Matinas BioPharma Holdings Inc (FRA:6LJ0)
€ 2.69 0 (0%) Market Cap: 3.23 Mil Enterprise Value: -7.02 Mil PE Ratio: 0 PB Ratio: 0.15 GF Score: 57/100

Q4 2021 Matinas BioPharma Holdings Inc Earnings Call Transcript

Mar 08, 2022 / 01:30PM GMT
Release Date Price: €25.75 (-1.90%)
Operator

Hello and welcome to the Matinas BioPharma fourth quarter and full year 2021 results conference call. (Operator Instructions) As a reminder, this conference is being recorded.

I would now like to turn the conference over to Peter Vozzo, Investor Relations Representative for Matinas BioPharma. Please go ahead, Peter.

Peter Vozzo
Westwicke Partners, LLC - MD

Thank you, Kevin. Good morning, everyone. And thank you for joining the Matinas BioPharma fourth quarter and full year 2021 results conference call. Early this morning we issued a press release with our financial results along with the business updates. The release is available on the Matinas BioPharma website under the investor section.

Speaking on today's call will be Jerry Jabbour, Chief Executive Officer and Keith Kucinski, Chief Financial Officer. We also have Dr. Terry Ferguson, Chief Medical Officer; Dr. Terri Matkovits, Chief Development Officer; Mr. Thomas Hoover, Chief Business Officer; and Dr. Raphael Mannino, Chief Scientific Officer who will be available to answer questions

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot